论文部分内容阅读
目的 :研究以国产长春瑞滨 (VNLB盖诺 )为主的不同联合化疗方案治疗晚期非小细胞肺癌的临床疗效及其毒性反应。方法 :选择 73例不能手术的Ⅲb～Ⅳ期非小细胞肺癌病人 ,随机分为 3组 ,分别采用NP方案、INP方案及VNP方案治疗。结果 :INP方案有效率为 6 0 % ,中位生存期为 5 6周 ;似高于NP及VNP方案。但统计学上无明显差异 (P >0 0 5 )。结论 :盖诺与顺铂、异环磷酰胺或VP 16联合治疗晚期非小细胞肺癌 (NSCLC)疗效好 ,毒性反应可以耐受
Objective: To study the clinical efficacy and toxicity of different combinations of chemotherapy with vinorelbine (VNLB) in combination with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Seventy-three patients with unresectable stage Ⅲb-Ⅳ non-small cell lung cancer were randomly divided into 3 groups. They were treated with NP regimen, INP regimen and VNP regimen respectively. Results: The effective rate of INP regimen was 60% and the median survival time was 56 weeks, which was higher than that of NP and VNP. But no statistically significant difference (P> 0 0 5). CONCLUSION: The combination of Ginorone and cisplatin, ifosfamide or VP 16 in the treatment of advanced non-small cell lung cancer (NSCLC) is effective and the toxic response can be tolerated